Page 9 - Thomas Hoffmann News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Share this article Share this article ROSEMONT, Ill., March 9, 2021 /PRNewswire/ -- Certain gum disease-related variables improve five years after the early removal of nearby unerupted wisdom teeth in young patients, according to a new study. In the study published in the March issue of the Journal of Oral and Maxillofacial Surgery, the official journal of the American Association of Oral and Maxillofacial Surgeons (AAOMS), average probing pocket depth (PPD) and clinical attachment level (CAL) of the teeth – the second molars – are variables that improve over time after removal of the a...

Search jobs 08-Mar-2021 Austhera BioSciences, Inc. to Present at the Upcoming 2021 Spring Private Company Showcase Hosted by Credit Suisse, Solebury Trout, and Cooley GEORGETOWN, Texas--(BUSINESS WIRE)--Austhera BioSciences, Inc. today announced that Edward Rudnic, CEO and David Snyder, CFO will present an overview of the company at the upcoming 2021 Spring Private Company Showcase hosted by Credit Suisse, Solebury Trout, and Cooley. During the 20-minute presentation, participants will be able to submit questions electronically with answers provide...

Published: Feb 10, 2021 NEW YORK & SAN DIEGO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Enoch Kariuki, PharmD, to its Board of Directors. Dr. Kariuki is a highly accomplished finance executive, bringing over a decade of deep expertise in life sciences investment banking, strategic advising and business development to Zentalis. “We are pleased to welcome ...

Landos Prices $ 100 Million IPO RTW Venture Fund Limited (the "Company"),  the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector,  is pleased to note the announcement by its portfolio company Landos Biopharma, Inc. ("Landos") on 03 February 2021 of its pricing of a $ 100 million initial public offering ("IPO") and admission to trade on Nasdaq Global Market under ticker "LABP". Landos  is a clinical-stage biopharmaceut...

Landos Biopharma Announces Pricing of Initial Public Offering February 03, 2021 20:13 ET | Source: Landos Biopharma, Inc. Landos Biopharma, Inc. Blacksburg, Virginia, UNITED STATES BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross pro...